10-Q: Vivani Medical Reports Q3 2024 Results, Advances GLP-1 Implant Program

Vivani Medical's Q3 2024 report highlights progress in its GLP-1 implant program, including a redesigned clinical trial and positive preclinical data, while also showing a net loss for the quarter.

Summary

• Vivani Medical, a preclinical stage biopharmaceutical company, released its financial results for the third quarter of 2024.
• The company is focused on developing miniaturized, subdermal implants using its NanoPortal technology for long-term drug delivery.
• Vivani's lead program, NPM-115, a six-month GLP-1 implant for chronic weight management, is a key priority.
• The company has redesigned its first-in-human study, LIBERATE-1, to evaluate the exenatide implant in obese and overweight patients.
• Preclinical data showed the exenatide implant generated a 20% weight loss in obese mice, comparable to semaglutide injections.
• The company received regulatory approval to initiate the LIBERATE-1 clinical trial in Australia, with data expected in 2025.
• Vivani reported a net loss of $6.041 million for the three months ended September 30, 2024, and $17.436 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents were $19.646 million as of September 30, 2024.
• Vivani estimates that its current cash will be sufficient to meet its obligations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in the company's GLP-1 implant program and preclinical data, the company is still in the preclinical stage, has no revenue, and is incurring significant losses. The need for additional capital and the risks associated with clinical trials temper the positive aspects.

Positives

• The company is making significant progress in its GLP-1 implant program.
• Preclinical data for the exenatide implant is promising, showing comparable weight loss to semaglutide.
• The company has secured regulatory approval to initiate its first in human clinical trial in Australia.
• Vivani has a strategic focus on the obesity market, which has high unmet medical needs.
• The company has secured additional funding through a securities purchase agreement and an at-the-market sales agreement.
• The company's GLP-1 implant showed an 82% reduction in liver fat in an obese mouse model.

Negatives

• Vivani reported a net loss of $6.041 million for the three months ended September 30, 2024, and $17.436 million for the nine months ended September 30, 2024.
• The company has incurred recurring operating losses and negative operating cash flows since inception.
• The company is still in the preclinical stage and has no revenue.
• The company is dependent on raising additional capital to continue operations.
• The company's clinical trial for NPM-119 was previously on full clinical hold due to insufficient CMC information.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and/or developing profitable operations.
• Clinical trials are expensive and have uncertain outcomes, with potential for delays or negative results.
• The company is subject to extensive regulation by the FDA and other regulatory agencies.
• The company may face challenges in developing and commercializing its product candidates.
• The company may not be able to attract the attention of research analysts at major brokerage firms due to its non-traditional path to becoming a public company.
• The company is involved in ongoing litigation with Pixium Vision SA, which could result in additional costs and diversion of management resources.

Future Outlook

Vivani estimates that its current cash will be sufficient to meet its planned obligations for at least the next twelve months. The company anticipates initiating the LIBERATE-1 clinical trial in the fourth quarter of 2024, with data expected in 2025.

Management Comments

• Vivanis main priority is the further development of its lead program NPM115, a miniature, 6 -month, GLP1 implant candidate for chronic weight management.
• Vivanis management team remains committed to identifying and exploring strategic options that will enable further development of its pioneering neurostimulation systems.
• Moving forward, Vivanis focus will be on the further development of NPM115 and its emerging pipeline of innovative miniature, long-term drug implants to treat patients with chronic diseases and high unmet medical need.

Industry Context

Vivani's focus on long-acting GLP-1 implants aligns with the growing demand for effective and convenient treatments for obesity and type 2 diabetes. The company's technology aims to address medication non-adherence, a significant challenge in chronic disease management. The shift to prioritize the obesity portfolio reflects the market potential and unmet needs in this area.

Comparison to Industry Standards

• The preclinical weight loss data of 20% in obese mice is comparable to results seen with semaglutide injections (Ozempic/Wegovy), which are established treatments in the obesity market.
• The company's GLP-1 implant's 82% reduction in liver fat in an obese mouse model is consistent with published results from similar investigations with semaglutide.
• The company's focus on long-acting implants addresses a key challenge in the industry, which is medication adherence, and differentiates it from daily or weekly injectable treatments.
• The company's use of NanoPortal technology for controlled drug release is a novel approach compared to traditional drug delivery methods.
• The company's strategic shift to prioritize the obesity portfolio is in line with the growing market demand for effective weight management solutions, as seen with the success of drugs like Ozempic and Wegovy.

Management Changes

Legal Proceedings

• One opposition filed by Pixium Vision SA (Pixium) is pending in the European Patent Office challenging the validity of a European patent owned by Cortigent.
• The company is involved in ongoing litigation with Pixium Vision SA related to a terminated Memorandum of Understanding (MOU).

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Employees may be affected by potential future reductions in force.
• Patients may benefit from the development of new long-acting drug delivery options.
• The company's suppliers and partners may be impacted by the company's financial performance and strategic decisions.

Next Steps

• Initiate the LIBERATE-1 clinical trial in Australia in the fourth quarter of 2024.
• Continue development of the NPM-115 program and other long-acting drug implant candidates.
• Explore strategic options for the neurostimulation division.
• Seek additional funding through public or private equity offerings or debt financings, grants, collaborations, strategic partnerships or other sources.

Key Dates

Keywords

GLP-1 implant, obesity, weight management, NanoPortal technology, exenatide, semaglutide, clinical trial, drug delivery, biopharmaceutical, subdermal implant